Leuprolide (Lupron)

General information

Class/mechanism: GnRH (gonadotropin-releasing hormone)/LHRH (luteinizing hormone releasing hormone) agonist; inhibits gonadotropin secretion, decreasing circulating levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone), and suppressing synthesis of ovarian and testicular steroids.
Route: IM
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Breast cancer
• Prostate cancer

Patient drug information

• Leuprolide (Lupron) patient drug information (Chemocare)
• Brief patient counseling information can be found in the Leuprolide (Lupron) package insert
• Brief patient counseling information can be found in the Leuprolide (Eligard) package insert
• Leuprolide (Lupron) patient drug information (UpToDate)

History of changes in FDA indication

• 4/09/1985: Initial FDA approval for palliative treatment of advanced prostate cancer.

Also known as

Eligard, leuprolide acetate, Lupron Depot, Leupromer, Leuprorelin, Prostap SR, Prostap 3, or Viadur.